Results 91 to 100 of about 122,325 (212)

Association Between Hepatitis C Virus Infection and SYNTAX Score in Patients with ST-Segment Elevation Myocardial Infarction: A Propensity Score-Matched Analysis. [PDF]

J Clin Med
Balaban I, Tanyeri Uzel S, Caglayan E, Ceneli D, Eminoglu H, Kultursay B, Keten MF, Biyikli K.   +7 more
europepmc   +1 more source

Hepatitis C virus infection dynamics, treatment, and lipid nanoparticle-mediated infection in humanized liver chimeric mouse models. [PDF]

Sci Adv
Park SB, Sánchez-Meza J, Umarova R, Shields J, Collignon L, Sula X, Holmbeck K, Oh JH, Farci P, Tyrrell DL, Feld JJ, Bukh J, Rice CM, Liang TJ.   +13 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Moving Toward Hepatitis C Elimination in Haemodialysis: HCV Antigen as a Practical Screening Alternative. [PDF]

Cureus
Koh SJ, Liou WL, Gan S, Liu PY, Phang CC, Chow WC, Kumar R.   +6 more
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

The Last Mile: Understanding Barriers to Hepatitis C Virus Microelimination Among People with HIV in San Francisco, 2021-2024. [PDF]

Open Forum Infect Dis
Haser GC, Sanchez MA, Grinstein R, Habib A, Ongpin MM, Pipkin S, Terzian AS, Luetkemeyer AF, Cohen SE.   +8 more
europepmc   +1 more source

Targeting Egfr‐Mediated Cell Proliferation and Lipid Metabolism Separation Effectively Accelerate Liver Regeneration

Cell Proliferation, EarlyView.
AREG coordinates cell proliferation and lipid metabolism reprogramming during liver regeneration and targeting lipid metabolism can promote liver regeneration. ABSTRACT Hepatocyte proliferation restores liver mass after partial hepatectomy (PHx), but the metabolic cost of this process remains unclear.
Yuelei Hu, Shifei Song, Ruilin Wang, Ni An, Jinmei Diao, Yuguo Chen, Juan Liu, Guoyue Lv   +7 more
wiley   +1 more source

Low-Barrier Fibrosis Screening in Hepatitis C Treatment: The Decompensated Cirrhosis in Hepatitis C Evaluation Questionnaire. [PDF]

J Viral Hepat
Spencer H, Brumbach B, Geduldig A, Nelson L, Seaman A.   +4 more
europepmc   +1 more source

A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer

The FEBS Journal, EarlyView.
Matrix metalloproteinases (MMPs) orchestrate cancer progression and metastasis through proteolytic and non‐proteolytic actions. By remodeling the tumor microenvironment, enhancing growth factor availability, and modulating cell behavior, MMPs promote proliferation, migration or invasion, and epithelial‐to‐mesenchymal transition. Alongside extracellular
Zoi Piperigkou, Sylvia Mangani, Spyros Kremmydas, Nikolaos E. Koletsis, Nikos K. Karamanos   +4 more
wiley   +1 more source

Evaluating Pay-It-Forward Strategy to Promote Hepatitis B Virus and Hepatitis C Virus Testing Among International Migrants From Low- and Middle-Income Countries in China: Protocol for a Cluster Randomized Controlled Trial. [PDF]

JMIR Res Protoc
Xiong M, Marley G, Muheyati A, Gao M, Cao H, Enders K, Huang S, Tucker J, Wang C.   +8 more
europepmc   +1 more source